Skip to content

18F-Fluoride Assessment of Aortic Bioprosthesis Durability and Outcome

18F-Fluoride Assessment of Aortic Bioprosthesis Durability and Outcome

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02304276
Acronym
18F-FAABULOUS
Enrollment
105
Registered
2014-12-01
Start date
2015-01-31
Completion date
2020-10-30
Last updated
2024-05-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart; Complications, Valve, Prosthesis

Brief summary

This study will evaluate the two main types of replacement tissue heart valve used in current practice, comparing outcomes from surgical aortic valve replacement (AVR) with that of the more recently introduced key-hole procedure called transcatheter aortic valve implantation (TAVI). Participants will be recruited at various time points ranging from 1 month to 10 years following valve replacement with either AVR or TAVI. It is thought that progressive calcium (chalk) formation is responsible for the failure of the majority of these valves. All participants will therefore have a PET-CT scan with a special type of tracer called 18F-fluoride in order to measure active calcium formation in the valve. They will then have annual clinical follow-up for 5 years and be invited back for a repeat CT scan at 2 years to measure change in calcium burden. This study aims to investigate, firstly, the effects of valve age and type on calcium formation as measured by PET-CT and, secondly, whether this measure of calcium formation can help to predict how long different types of valve will last. If successful, 18F-fluoride PET-CT could become a valuable tool for testing new treatments to improve valve longevity and new valve designs.

Detailed description

Aortic stenosis is the commonest form of valve disease in the western world and the leading indication for valve surgery. Bioprosthetic valves are known to degenerate via a process that is predominantly driven by calcification. Transcatheter aortic valve implantation (TAVI) has recently emerged as a less invasive alternative to conventional aortic valve replacement (AVR) surgery. Whilst this technique holds great promise, long-term follow up data are lacking and the longevity of these valves remains to be established. In this longitudinal, cross-sectional study of 180 subjects with either surgical or transcatheter implanted bioprostheses, this study proposes to look for the earliest signs of active calcification using 18F-fluoride positron emission tomography (PET). During a 5 year follow-up period, this study hopes to demonstrate that 18F-fluoride PET will predict subsequent bioprosthetic valve degeneration and identify patients at risk of premature valve failure. The study also hopes that it will inform about the comparative durability of novel percutaneous valves. If successful, 18F-Fluoride could provide a useful method of assessing novel therapeutic strategies targeted at improving the longevity of bioprostheses and help to guide future valve design.

Interventions

RADIATION18F-Fluoride PET-CT

Injection of 18F-Fluoride with target activity 125MBq giving an anticipated radiation exposure of 3mSv CT scanning protocol giving an anticipated radiation exposure of 13mSv

RADIATIONCT calcium score of aortic valve

CT associated with an anticipated radiation exposure of 3mSv (Cohorts 2 and 3 only)

Sponsors

NHS Lothian
CollaboratorOTHER_GOV
Cambridge University Hospitals NHS Foundation Trust
CollaboratorOTHER
Papworth Hospital NHS Foundation Trust
CollaboratorOTHER_GOV
Bichat Hospital
CollaboratorOTHER
University of Edinburgh
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
40 Years to No maximum
Healthy volunteers
No

Inclusion criteria

Cohort 1 * able to provide informed consent * aged over 40 years * patients with a bioprosthetic aortic valve who are due to undergo a redo-surgical aortic valve replacement Cohort 2 * able to provide informed consent * aged over 40 years * patients at 1 month (n=10), 2 years (n=20), 5 years (n=20) and 10 years (n=20) following surgical bioprosthetic aortic valve replacement Cohort 3 * able to provide informed consent * aged over 40 years * patients at 1 month (n=10), 2 years (n=20) and 5 years (n=20) following transcatheter aortic valve implantation (TAVI) with the Edward's SAPIEN and the COREVALVE.

Exclusion criteria

* Inability to give informed consent * Pregnancy * Breastfeeding * Claustrophobia * Allergy to iodinated contrast * Liver failure * Chronic kidney disease (with estimated glomerular filtration rate \<30 mL/min) * Metastatic malignancy * Paget's disease

Design outcomes

Primary

MeasureTime frameDescription
18F-Fluoride uptake in aortic bioprosthesesBaseline18F-Fluoride uptake expressed as tissue to background ratio (TBR) in aortic valve bioprostheses of different age and type as measured by PET/CT

Secondary

MeasureTime frameDescription
CT calcium score of aortic valveBaseline and 2 yearsChange in aortic valve calcium score (Agatston units) from baseline to 2 years as determined by CT
Echocardiographic evaluation of aortic valve functionBaseline, 1 year and 2 yearsChange in echocardiographic parameters of aortic valve function (both stenosis and regurgitation) from baseline to 1 year and 2 years as determined by Doppler echocardiography
Frequency of major adverse cardiovascular events5 yearsFrequency of major adverse cardiovascular events (cardiovascular death, myocardial infarction, stroke, admission with heart failure, repeat valve surgery) as determined by annual clinical follow-up of study population over 5 years
Immunohistochemical staining of explanted aortic bioprostheses for marker of calcificationintraoperativeImmunohistochemical staining for markers of mineralisation (alkaline phosphatase, Runx-2, osteocalcin) in explanted aortic valve bioprostheses expressed as a percentage of total valve surface area.

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 3, 2026